Key Takeaways
- Switching to aflibercept 8 mg was associated with modest visual gains and reduced retinal fluid in previously treated eyes with nAMD.
- Eyes switched because of non-response showed the greatest anatomical and visual improvements, with benefits maintained through 6 months.
Switching to aflibercept 8 mg was associated with modest visual gains and improved retinal anatomy in previously treated eyes with neovascular age-related macular degeneration (nAMD), with benefits maintained through 6 months, according to a study.
Investigators evaluated outcomes in eyes (N = 300) that were switched to aflibercept 8 mg after prior anti-vascular endothelial growth factor therapy because of non-response, suboptimal response, or durability-related reasons. In the 6 months before the switch, mean best-corrected visual acuity declined by 1.9 letters and central subfield thickness increased.
By 3 months after switching, best-corrected visual acuity improved by 2.0 letters overall, with the largest gain seen in eyes switched for non-response, which improved by 2.8 letters. Mean central subfield thickness decreased by 45.3 µm, and retinal fluid was also reduced.
Anatomical improvements were most pronounced in eyes switched because of non-response, while eyes switched for suboptimal response or durability-driven reasons showed more modest but consistent changes. Visual and anatomical outcomes were maintained at the 6-month follow-up.
Reference
Veritti D, Sarao V, Lupidi M, et al. Switching to aflibercept 8 mg in neovascular age-related macular degeneration: real-world outcomes according to switch indication. Graefes Arch Clin Exp Ophthalmol. 2026;doi: 10.1007/s00417-026-07362-6. Epub ahead of print. PMID: 42406041.
Related Content
